A Former Senator’s Fight Against Pancreatic Cancer Illuminates Hope in Revolutionary New Therapy
When Ben Sasse, a former U.S. senator from Nebraska, received a diagnosis of metastatic pancreatic cancer in December, he swiftly prioritized action over comfort. His resolve was to pursue every possible avenue to extend his life and enhance its quality, a path that led him to an early-phase clinical trial. "If we were to have much of a chance of living longer than the three to four months they were giving us at that point, we were going to need to get into an aggressive trial," Sasse shared with STAT last month. This pursuit of hope has placed him at the forefront of a potentially groundbreaking development in pancreatic cancer treatment, centered on Revolution Medicines’ investigational drug, daraxonrasib.
The pancreatic cancer community has been keenly observing the progress of daraxonrasib, a next-generation targeted therapy, particularly after Revolution Medicines (often referred to as Rev Med) released early-phase data. Even before the company announced positive topline Phase 3 results from the RASolute 302 trial on Monday, pancreatic cancer experts harbored a strong conviction that the drug would likely achieve regulatory approval. These recent findings have only amplified that optimism, offering tangible evidence of daraxonrasib’s potential to significantly alter the treatment landscape for advanced pancreatic cancer.
Daraxonrasib: A Beacon of Hope in Advanced Pancreatic Cancer
The RASolute 302 trial’s topline results have provided significant encouragement. The study demonstrated that daraxonrasib, when used as a second-line therapy for advanced pancreatic cancer patients, can substantially improve survival rates. Patients receiving daraxonrasib experienced a median survival of 13.2 months, a notable increase compared to the 6.7 months achieved with traditional chemotherapy. The implications of using daraxonrasib even earlier, as a first-line therapy, as Sasse has done, suggest the potential for even more profound benefits over current standard-of-care chemotherapy regimens.
For Ben Sasse, this investigational treatment may have already extended his life beyond the initial grim prognosis of a few months given at the time of his diagnosis in December. "Given what the prognosis was," he reflected, "and given what the tables say about pancreatic cancer, this experience has seemingly extended both quantity and quality of life." His personal journey, intertwined with the scientific advancement of daraxonrasib, offers a compelling narrative of hope and resilience in the face of a notoriously aggressive disease.
STAT engaged in an in-depth conversation with Sasse about his experience with daraxonrasib, as part of an upcoming feature exploring the scientific breakthrough behind this novel drug. The following interview has been edited for conciseness and clarity, providing a personal perspective on a medical development with far-reaching implications.
The Unforeseen Diagnosis: From Farm Labor to Tumors
The initial symptoms that alerted Sasse to a serious health issue began subtly in October. Persistent and significant back pain, which he initially attributed to his background of farm work and familiarity with physical exertion, started to feel distinctly abnormal. "I’m not the toughest guy, but grew up working on the farm. I’m used to some aches and pains. But I knew something was weird because the pain was significant," he recounted. The pain manifested as radiating pressures in his back, accompanied by peculiar stomach cramping, consuming approximately 70% of his waking hours. The discomfort was so severe that he would often be doubled over.
Despite these alarming symptoms, initial blood tests revealed no abnormalities. His physician, recognizing the need for further investigation, scheduled him for diagnostic scans. The call from his doctor arrived on a Friday morning, the day before his child’s college graduation. His doctor, clearly stressed and hesitant to deliver devastating news over the phone, initially attempted to buffer the information. However, Sasse insisted on receiving the unvarnished truth. "He said, ‘your torso has got a lot of tumors. And we’ve got a mass in the pancreas that is very significant.’"
Confronting Mortality: Faith, Family, and the Urgency of Life
The gravity of the diagnosis was immense, yet Sasse’s immediate response was characterized by a profound sense of purpose focused on his family. He requested biopsies be scheduled for the following Monday, deliberately postponing his personal reflection to ensure he could fully participate in his child’s graduation ceremony. This decision was deeply rooted in his faith and his commitment to his loved ones. "Theology was issue one. As a Christian, there’s a phrase: to live is Christ and to die is gain," he explained. "Issue two was thinking about, how do I love all my kids and wife in the time I have left." He felt it was imperative not to allow the impending diagnosis to overshadow such a significant family milestone. This deliberate choice to compartmentalize his fear and grief allowed him to remain present for his family during a critical moment.
The Quest for a Trial: Navigating the Medical Landscape
The path forward was clear: traditional chemotherapy offered little hope, and an aggressive clinical trial was his best chance for survival. The immediate challenge was identifying where such a trial could be accessed. Sasse and his family quickly focused on leading cancer research institutions, MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, as potential sites for comprehensive tumor genetic profiling. The ensuing six days were a whirlwind of appointments and evaluations, with Sasse dedicating a day and a half to each institution. The consensus from the medical teams was stark: traditional chemotherapy was unlikely to yield a significant outcome, a reality underscored by the historically poor survival rates associated with pancreatic cancer.
It was at MD Anderson that Sasse first heard about the potential of daraxonrasib. Subsequently, he traveled to Memorial Sloan Kettering to consult with Dr. Eileen O’Reilly, a physician he had been informed was a leading expert in pancreatic cancer in the United States. Dr. O’Reilly’s counsel was direct and encouraging: "If you have a shot to get into the trial, I’d take it." This recommendation solidified his resolve, and the focus shifted to the process of enrollment. The days that followed were filled with anticipation as he awaited confirmation of his eligibility for the Revolution Medicines trial.
The Trial Experience: Navigating Side Effects and Measuring Progress
Sasse’s experience on daraxonrasib has been marked by significant clinical benefits, though disentangling these from the effects of pain management has been a complex process. The intense back pain he endured prior to starting the trial was a primary concern. Upon commencing daraxonrasib, he experienced a resurgence of this pain, which he described as "terrible." This was compounded by his concurrent use of morphine for pain relief. However, his medical oncologist at MD Anderson, Dr. Bob Wolff, provided a crucial perspective: the worsening pain could be an indicator that the tumor was responding to the treatment.
Adding to the challenging initial phase, Sasse also experienced "massive facial bleeding," necessitating a temporary pause in the treatment to manage the complication with antibiotics before resuming daraxonrasib. Despite these hurdles, the objective markers of his cancer have shown dramatic improvement. His CA 19-9 levels, a common blood marker for pancreatic cancer, have plummeted. Prior to the trial, these levels were above 8,000. By mid-March, they had fallen to 374, a significant decline that indicated a substantial reduction in tumor volume, estimated at around 60%. Concurrently, his pain has significantly diminished, a testament to both the drug’s efficacy and improved pain management.
A New Era for Pancreatic Cancer Treatment
The development of daraxonrasib represents one of the most significant advancements in pancreatic cancer treatment in decades. For Sasse, being a participant in this trial carries profound meaning. "First of all, I’m incredibly grateful to the folks who dedicate their time and talent to this research," he stated. He lauded the expertise and dedication of his care team at MD Anderson, including Drs. Bob Wolff and Shubham Pant, recognizing that the primary purpose of a clinical trial is to generate data that will benefit future patients.
"But I’m incredibly grateful to the whole team at MD Anderson and the way they’ve treated us," Sasse continued. "It’s been amazing care. The fact that I don’t have to be permanently hospitalized. I can get out of the hospital, get extended time with my family." This ability to maintain a degree of normalcy and spend precious time with his loved ones, even amidst aggressive treatment, underscores the potential of such innovative therapies not only to extend life but also to preserve its quality.
The Scientific Underpinnings of Daraxonrasib
Daraxonrasib targets a specific pathway in cancer cells that is often mutated and overactive in pancreatic cancer, known as the KRAS pathway. Mutations in the KRAS gene are found in approximately 90% of pancreatic ductal adenocarcinomas, making it one of the most frequently mutated genes in the disease. For years, KRAS was considered an "undruggable" target due to the protein’s complex structure and its role in fundamental cellular processes. However, scientific advancements have led to the development of targeted therapies that can inhibit specific mutated forms of KRAS.
Daraxonrasib is designed to inhibit mutated KRAS proteins, particularly the G12D variant, which is prevalent in pancreatic cancer. By blocking the signaling cascade initiated by these mutated proteins, the drug aims to halt or slow tumor growth. The development of such targeted therapies represents a paradigm shift from traditional chemotherapy, which often has broad cytotoxic effects on both cancerous and healthy cells, leading to significant side effects. Targeted therapies offer the promise of greater efficacy with potentially fewer and more manageable side effects, as suggested by Sasse’s experience with improved quality of life alongside tumor response.
Broader Implications and Future Outlook
The positive results from the RASolute 302 trial, particularly when considering daraxonrasib’s potential as a first-line therapy, could fundamentally alter the treatment landscape for pancreatic cancer. This disease has long been characterized by its aggressive nature, late diagnosis, and limited effective treatment options, resulting in a five-year survival rate that has historically hovered around 10-12%.
The success of daraxonrasib in extending survival and improving quality of life for patients like Ben Sasse offers a much-needed beacon of hope. If approved, it would provide oncologists with a powerful new tool to combat this devastating illness. Furthermore, the ongoing research and development in targeted therapies for pancreatic cancer, exemplified by daraxonrasib, signal a promising future for patients. The continued investigation into drug combinations and novel therapeutic strategies, informed by trials like RASolute 302, holds the potential to further improve outcomes and move closer to transforming pancreatic cancer from a terminal diagnosis into a manageable chronic condition. The personal journey of Ben Sasse, from a devastating diagnosis to a hopeful participant in a cutting-edge clinical trial, underscores the critical importance of research and innovation in the relentless fight against cancer.
